Compare · CNSY vs MDLN
CNSY vs MDLN
Side-by-side comparison of Cerenome Inc. (CNSY) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNSY and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.51B, about 7416.6x CNSY ($6.9M).
- MDLN has been more active in the news (17 items in the past 4 weeks vs 10 for CNSY).
- MDLN has more recent analyst coverage (25 ratings vs 0 for CNSY).
- Company
- Cerenome Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $6.9M
- $51.51B
- 1M return
- -
- +10.48%
- 1Y return
- -
- -3.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 10
- 17
- Recent ratings
- 0
- 25
Cerenome Inc.
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Latest CNSY
- Cerenome Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
- Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
- SEC Form 10-Q filed by Cerenome Inc.
- Cerenome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
- Chief Business Officer Andrews Ronald Asbury was granted 92,858 stock options (SEC Form 4)
- Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
- Cerenome Appoints Director Ron Andrews as Chief Business Officer
- Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers
- SEC Form EFFECT filed by Medline Inc.
- Medline Inc. announces pricing of secondary offering of Class A common stock
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.